- Pharma company financial support for CME in the US has fallen for the fourth year in a row: from $1.2 billion in 2007 to $736 million in 2011
- To minimise CME risks, many large pharma companies have stopped funding CME projects executed by commercial providers, and others are following suit
- Outside the US, an increasing number of pharma companies are now aligning their investments with independent medical education (IME)
- Stricter CME guidelines in the US and Europe are prompting more companies to hand over budgetary control to regulatory teams
So what role could or should the pharmaceutical industry play in medical education for healthcare professionals? And what should it expect in return for its investments? Find out in one convenient, compelling new FirstWord Dossier report: Pharma’s Future Role in CME.
Save time and effort by reviewing forecasts from 10 leading figures in the US and European CME fields. In this report, they analyse the emerging trends, radical changes, and major risks affecting future medical education. These opinion leaders also examine whether it would be better for the industry to take a leading role in future CME productions, or strategically direct these from the background.
Key Report Features
- Recent and expected US and European CME regulations
- Latest pharma approaches to minimising risk in CME
- Growing use of independent medical education (IME)
- Comparative differences between CME vs IME
- Potential effects of CME funding from other providers
- Key factors affecting future pharma investment in CME
- Opportunities in eCME and online medical education
- Internal pharma company changes for managing CME
- Understand the issues affecting CME in US and Europe
- Review your future CME, IME and eCME options
- Assess other medical education funding sources
- Evaluate the quality and efficacy of your CME content
- Explore the benefits of eCME for physicians and pharma
- Identify your company’s ultimate goal for CME programs
- Start planning your next medical education strategies
- Improve your potential medical education outcomes
Who Would Benefit From This Report?
This report will be of value to pharma directors and managers with responsibilities in the following areas:
- Market access
- Continuing medical education
- Regulatory affairs
- Medical affairs
- Marketing management
- Business development
- Brand marketing
- Key Opinion Leader liaison
- Corporate communications
Key Questions Answered:
- What are the primary factors affecting US and European CME?
- How are medical education providers having to adapt?
- Should physicians be responsible for funding their own CME?
- What are the key differences between CME and IME?
- What ROI can pharma expect from IME investments?
- Could eCME take over from face-to-face CME?
- Who should be managing internal pharma CME budgets?
- What do physicians think about the quality of CME content?
Industry pushed towards the side-lines
- From dark days to Sunshine Act
- Minimising risk is the new priority
- Europe following the US model
- European disunion?
- The push for new European guidelines
- Crossing borders
Sharing the responsibility of medical education
- Increased risk, reduced funding
- Collaborative approaches in CME
- Other potential sources of funding
- Should physicians be responsible for their own medical education?
- Evaluating IME vs CME
- So what are the differences between CME and IME?
- Regulating IME
- Industry involvement in IME
- How medical education providers are having to adapt?
- The grants system: Help or hindrance?
- The logistical challenge
- What is the ROI for industry?
- Improving patient outcomes
- Internal structures altering
- Is the quality of CME improving?
- The benefits of e-learning